Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH’s Blood

Pharming Group N.V. announces today that the positive results of a Phase 3 clinical trial of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, have been published in Blood, . Data from this study was previously announced on February 2, 2022. “As we continue to seek a better understanding of APDS as a recently characterized rare disease, we remain committed to sharing our findings with researchers and doctors around the world." — Anurag Relan MD, MPH | Chief Medical Officer Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗